Cargando…

Tyrosine Kinases in Cancer

Detalles Bibliográficos
Autores principales:	Blau, Olga, Afanasyev, Boris, Blau, Igor Wolfgang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2015
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631159/ https://www.ncbi.nlm.nih.gov/pubmed/26582532 http://dx.doi.org/10.4137/BMI.S34403

Ejemplares similares

Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy
por: Blau, Olga, et al.
Publicado: (2014)

Fasting plus tyrosine kinase inhibitors in cancer
por: Caffa, Irene, et al.
Publicado: (2015)

Receptor Tyrosine Kinases — Expanding Horizons
por: Hafizi, Sassan
Publicado: (2014)

Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012)

Lemur tyrosine kinase-3 (LMTK3) in cancer and evolution
por: Stebbing, Justin, et al.
Publicado: (2011)

Targeting Tyrosine Kinases in Cancer: Lessons for an Effective Targeted Therapy in the Clinic
por: Angelucci, Adriano
Publicado: (2019)

Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia
por: Berenstein, Rimma, et al.
Publicado: (2015)

Comparative examination of various PCR-based methods for DNMT3A and IDH1/2 mutations identification in acute myeloid leukemia
por: Berenstein, Rimma, et al.
Publicado: (2014)

Complete remission with tyrosine kinase inhibitors in renal cell carcinoma
por: Wada, Yoshihiro, et al.
Publicado: (2012)

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
por: Tiribelli, Mario, et al.
Publicado: (2019)

P828: EFFECT OF ANTI-CD38 MONOCLONAL ANTIBODIES ON THE INTERACTION OF MYELOMA CELLS WITH BONE MARROW STROMAL CELLS
por: Lienhart, Malgorzata, et al.
Publicado: (2023)

Targeting the tyrosine kinase inhibitor-resistant mutant EGFR pathway in lung cancer without targeting EGFR?
por: De Greve, Jacques, et al.
Publicado: (2020)

Efficacy and Pharmacologic Data of Second-Generation Tyrosine Kinase Inhibitor Nilotinib in BCR-ABL-Positive Leukemia Patients with Central Nervous System Relapse after Allogeneic Stem Cell Transplantation
por: Reinwald, Mark, et al.
Publicado: (2014)

The Variations of MER Receptor Tyrosine Kinase and the Development of Chronic Obstructive Pulmonary Disease
por: Oh, Dong Kyu, et al.
Publicado: (2018)

The emerging landscape of EFGR tyrosine kinase inhibitors in lung adenocarcinoma—successes and challenges
por: Oduah, Eziafa I., et al.
Publicado: (2022)

Tyrosine Kinases and Endothelial Homeostasis in Pulmonary Arterial Hypertension: Too Hot to Handle?
por: Bogaard, Harm Jan, et al.
Publicado: (2022)

PD-L1 expression associated with better response to EGFR tyrosine kinase inhibitors
por: Rosell, Rafael, et al.
Publicado: (2015)

Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: are we actually ready?
por: Tabbò, Fabrizio, et al.
Publicado: (2020)

Chronic Myeloid Leukemia in Children and Adolescents: The Achilles Heel of Oncogenesis and Tyrosine Kinase Inhibitors
por: Moschovi, Maria, et al.
Publicado: (2021)

Moving the Needle Cautiously in Targeting One of the Most Often Acquired Receptor Tyrosine Fusion (RET Fusion) Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors
por: Zhang, Shannon S., et al.
Publicado: (2022)

Molecular investigation of Ewing sarcoma: about detecting translocations
por: Blau, Olga
Publicado: (2012)

Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases
por: Stern, David F
Publicado: (2000)

Multiple myeloma cells alter the senescence phenotype of bone marrow mesenchymal stromal cells under participation of the DLK1-DIO3 genomic region
por: Berenstein, Rimma, et al.
Publicado: (2015)

Tyrosine Kinase Inhibitor–Associated Platelet Dysfunction: Does This Need to Have a Significant Clinical Impact?
por: Ozgur Yurttas, Nurgul, et al.
Publicado: (2019)

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
por: Labots, Mariette, et al.
Publicado: (2016)

EGFR tyrosine kinase inhibitors (TKIs) for adjuvant therapy of early-stage non-small cell lung cancer (NSCLC): ready for the clinic?
por: Steuer, Conor E., et al.
Publicado: (2020)

Future prospects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and surgery for non-small cell lung cancer
por: Nagano, Tatsuya, et al.
Publicado: (2022)

Tyrosine kinase domain mutations in chronic myelogenous leukemia patients: Indian perspective
por: Ghosh, K
Publicado: (2022)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Tyrosine kinase – Role and significance in Cancer
por: Paul, Manash K., et al.
Publicado: (2004)

Tyrosine kinase signalling in breast cancer
por: Hynes, Nancy E
Publicado: (2000)

MicroRNAs as predictive biomarkers of treatment response to tyrosine kinase inhibitors in hepatocellular carcinoma: how much is missing?
por: Gramantieri, Laura, et al.
Publicado: (2022)

The Role of c-Abl Tyrosine Kinase in Brain and Its Pathologies
por: Motaln, Helena, et al.
Publicado: (2023)

Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab
por: Chikaishi, Yasuhiro, et al.
Publicado: (2020)

Bruton’s tyrosine kinase inhibitors in the treatment of multiple sclerosis
por: Shulga, Olga, et al.
Publicado: (2023)

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
por: Yao, Yu, et al.
Publicado: (2023)

Targeting Tyrosine Kinases and Autophagy in Prostate Cancer
por: Kung, Hsing-Jien
Publicado: (2010)

Receptor tyrosine kinases: role in cancer progression
por: Sangwan, V., et al.
Publicado: (2006)

Establishing the role of tyrosine kinase 2 in cancer
por: Übel, Caroline, et al.
Publicado: (2013)

The Receptor Tyrosine Kinase AXL in Cancer Progression
por: Rankin, Erinn B., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5qi5m4vv26t6jeosnitgn2a539